Sees FY23 R&D expense $340M-$350M. Sees FY23 SG&A expense $390M-$400M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACAD:
- ACAD Earnings this Week: How Will it Perform?
- Acadia Pharmaceuticals initiated with a Buy at UBS
- Biotech Alert: Searches spiking for these stocks today
- Rivian upgraded, Qorvo downgraded: Wall Street’s top analyst calls
- Acadia Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
Questions or Comments about the article? Write to editor@tipranks.com